Published in Biotech Law Weekly, October 20th, 2006
"This achievement is significant for Bioxel's as it clearly demonstrates our ability to manufacture semi-synthetic taxanes using a high-efficiency patent protected route that will allow us to meet the demands of leading pharmaceutical companies" said Pascal Delmas, president and CEO of Bioxel Pharma.
"Bioxel will be sampling its clients with docetaxel API during the fourth quarter of 2006 and we plan to complete the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.